Showing 5601-5610 of 10114 results for "".
- EWG: UVA Protection of Most Sunscreens Just 25 Percent of Touted SPFhttps://practicaldermatology.com/news/ewg-most-sunscreens-comprise-just-25-percent-of-touted-spf/2460962/Many sunscreens offer just a quarter of their stated SPF protection against ultraviolet A rays, a new Environmental Working Group (EWG)
- Accure Acne Seeks to Raise Up To $20 Million Through Private Placement Offeringhttps://practicaldermatology.com/news/accure-acne-seeks-to-raise-up-to-20-million-through-private-placement-offering/2460776/Accure Acne, Inc. has launched a private placement offering on the M-Vest platform to raise up to $20 Million. Building on the research of R. Rox Anderson, MD, Accure Co-Founder and Chief Scientific & Medical Officer, Accure has developed the Accure Laser System, an&n
- Thiazide Diuretics Linked to Skin Cancer Riskhttps://practicaldermatology.com/news/thiazide-diuretics-linked-to-skin-cancer-risk/2460744/Use of certain blood pressure-lowering medications may increase risk for skin cancer, a new study shows. Researchers reviewed data for nearly 303,000 adults in Ontario over age 65 who were prescribed medications for high bl
- Hoth Therapeutics Gets Greenlight to Start Phase 1b Trial of BioLexa for AD in Australiahttps://practicaldermatology.com/news/hoth-therapeutics-gets-greenlight-to-start-phase-1b-trial-of-biolexa-for-ad-in-australia/2460627/Hoth Therapeutics, Inc. received Human Research Ethics Committee clearance to commence the first cohort of the Phase 1b clinical trial of
- TARGET-DERM Real-World Study Expandshttps://practicaldermatology.com/news/target-derm-real-world-study-expands/2460550/Target RWE is expanding its active longitudinal dermatology registry, TARGET-DERM (
- Amytrx Therapeutics Comes Out of the Gate Strong with Lead Program AMTX-100, Clinical Development Planshttps://practicaldermatology.com/news/amytrx-therapeutics-comes-out-of-the-gate-strong-with-lead-program-amtx-100-clinical-development-plans/2460531/Amytrx Therapeutics, Inc. is on the move. Founded in 2014, Nashville-based Amytrx is developing novel therapies for inflammatory diseases with lead program AMTX-100 currently in clinical development for dermatologic indications. AMTX-100 is a new anti-inflammatory therape
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- Cassiopea Scores FDA Approval for Winlevi (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptorhttps://practicaldermatology.com/news/cassiopea-scores-fda-approval-for-winlevi-clascoterone-cream-1-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor/2460513/The FDA has approved Winlevi (clascoterone cream 1%) for the treatment of acne in patients 12 years and older. "Th
- Promising Data from Dermavant's Phase 2b Study of Tapinarof in Psoriasishttps://practicaldermatology.com/news/promising-data-from-dermavants-phase-2b-study-of-tapinorof-in-psoriasis/2460405/Patients treated with once daily tapinarof 1% demonstrated improvement in PASI75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase
- Industry Responds to COVID-19: UCB, Galderma, Timeless Skin Carehttps://practicaldermatology.com/news/industry-responds-to-covid-19-ucb-galderma-timeless-skin-care/2460354/UCB. UCB is working with the Seattle Structural Genomics Center for Infectious Disease to identify crystal structures of SARS-CoV-2 proteins. In addition to provi